Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 12/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18914213 | 0.94 | PDK1 (0.49) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL18907740 | 0.90 | PKM (0.48) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL23481547 | 0.79 | PDK1 (0.63) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL9611268 | 0.79 | PDK1 (0.63) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL18654098 | 0.79 | PDK1 (0.63) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL5544456 | 0.77 | ALDH1A1 (0.50) | EPHX1SMN1; SMN2ALDH1A1EPHX2 | |
| SCHEMBL9611267 | 0.77 | ALDH1A1 (0.61) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL14243258 | 0.76 | PDK1 (0.59) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL942808 | 0.76 | PDK1 (0.59) | PDK1PDK2PDK3PDK4SIGMAR1 | |
| SCHEMBL22110497 | 0.76 | PDK1 (0.59) | PDK1PDK2PDK3PDK4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091602-A1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | PDK1 213/4885PDK2 276/4885PDK3 258/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | PDK1 45/4885PDK2 23/4885PDK3 20/4885 |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | PDK1 180/4885PDK2 102/4885PDK3 72/4885 |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | ACACA, ACACB, PC | PDK1 45/4885PDK2 23/4885PDK3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.